Literature DB >> 11418417

Perfusion-modulated MR imaging-guided radiofrequency ablation of the kidney in a porcine model.

A J Aschoff1, A Sulman, M Martinez, J L Duerk, M I Resnick, G T MacLennan, J S Lewin.   

Abstract

OBJECTIVE: This study was performed to test the hypothesis that temporary renal ischemia will result in increased thermal lesion size during radiofrequency thermal ablation in the kidney.
MATERIALS AND METHODS: Twelve kidneys were treated in six pigs that were placed under general anesthesia in the MR suite, using a 0.2-T open C-shaped MR imaging system. A 4-cm-long, 14-mm-diameter balloon catheter was placed into the aorta using a transfemoral approach, and the balloon was positioned proximal to the renal arteries via guidance with MR imaging. A 2-cm exposed-tip MR-compatible 17-gauge radiofrequency electrode was placed into one kidney under MR fluoroscopy using fast imaging with steady-state free precession (FISP) sequences. Thermal ablation was performed with the electrode tip temperature maintained at 90 +/- 2 degrees C for 10 min. This procedure was repeated in the contralateral kidney. The balloon was inflated during one ablation. Postablation images were obtained, the pigs were sacrificed, and both kidneys of each animal were harvested for pathologic correlation.
RESULTS: Technical success was achieved in all animals. The lesion measured 14.2 +/- 2.2 mm (mean +/- standard deviation) for the ischemic kidney versus 8.0 +/- 2.6 mm in the normally perfused kidney (p = 0.00002). No significant complications were noted. In all images, thermal lesions displayed low signal intensity with a sharp rim of high signal intensity best visualized using short tau inversion recovery (STIR) sequences with a mean accuracy of 1.3 +/- 1.2 mm when compared with pathologic findings and a mean contrast-to-noise ratio of 4.9 +/- 2.5.
CONCLUSION: We accept the hypothesis that temporary renal ischemia leads to a significantly increased radiofrequency ablation lesion size. We conclude that catheter-based balloon perfusion reduction is feasible, that the procedure does not lead to major complications, and that it can be performed using MR imaging as the sole imaging modality.

Entities:  

Mesh:

Year:  2001        PMID: 11418417     DOI: 10.2214/ajr.177.1.1770151

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  8 in total

Review 1.  Image-guided radiofrequency ablation of renal cell carcinoma.

Authors:  Andreas Boss; Stephan Clasen; Markus Kuczyk; Fritz Schick; Philippe L Pereira
Journal:  Eur Radiol       Date:  2006-10-05       Impact factor: 5.315

Review 2.  Renal artery embolization-indications, technical approaches and outcomes.

Authors:  Arnaud Muller; Olivier Rouvière
Journal:  Nat Rev Nephrol       Date:  2014-12-23       Impact factor: 28.314

3.  An automatic occlusion device for remote control of tumor tissue ischemia.

Authors:  Hamid El-Dahdah; Bei Wang; Guanglong He; Ronald X Xu
Journal:  Technol Cancer Res Treat       Date:  2010-02

4.  Effects of perfusion on radiofrequency ablation in swine kidneys.

Authors:  Isaac Chang; Igor Mikityansky; Diane Wray-Cahen; William F Pritchard; John W Karanian; Bradford J Wood
Journal:  Radiology       Date:  2004-05       Impact factor: 11.105

Review 5.  Radiofrequency ablation of renal tumors.

Authors:  Andreas H Mahnken; Rolf W Günther; Josef Tacke
Journal:  Eur Radiol       Date:  2004-05-19       Impact factor: 5.315

6.  [Magnetic resonance imaging in the evaluation of temperature-controlled radiofrequency volumetric tissue reduction].

Authors:  B A Stuck; J Köpke; J T Maurer; T Verse; A Eckert; C Düber; K Hörmann
Journal:  HNO       Date:  2003-04-09       Impact factor: 1.284

Review 7.  [Percutaneous radiofrequency ablation of renal cell cancer].

Authors:  J Tacke; A H Mahnken
Journal:  Radiologe       Date:  2004-04       Impact factor: 0.635

Review 8.  [Interventional oncology in urology].

Authors:  J Tacke
Journal:  Radiologe       Date:  2007-12       Impact factor: 0.803

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.